Arch Coal Inc. (NYSE:ACI) is requesting that more than 300 acres of agricultural land be reclassified in order to expand an existing coal-waste storage facility.  The board would have to approve the zoning board’s decision. Arch Coal Inc. (NYSE:ACI) belongs to Basic Materials sector. Its net profit margin is -24.30% and weekly performance is -23.58%. On last trading day company shares ended up $1.62. Arch Coal Inc. (NYSE:ACI) distance from 50-day simple moving average (SMA50) is -42.82%.

ArcelorMittal SA (NYSE:MT) has received a “BB+” credit rating from analysts at Morningstar. The firm’s “BB+” rating indicates that the company is an above-average default risk. They also gave their stock a four star rating. ArcelorMittal SA (ADR) (NYSE:MT) shares fell -1.01% in last trading session and ended the day at $12.80. MT return on assets is -1.50%. ArcelorMittal SA (ADR) (NYSE:MT) quarterly performance is -14.15%.

W. P. Carey Inc. (NYSE: WPC), a global net-lease real estate investment trust, announced today that it will release its financial results for the third quarter of 2014 prior to the market open on Tuesday, November 4, 2014. On 07 October, W. P. Carey Inc. (NYSE:WPC) shares fell -0.48% and was closed at $63.92. WPC EPS growth in last 5 year was -13.10%. W. P. Carey Inc. (NYSE:WPC) year to date (YTD) performance is 8.82%.

Digital Power Corporation (NYSEMKT:DPW) said it recently received two contracts. One of the contracts involves a custom switching solution for cloud-based data centers. The other contract involves custom power solutions for cable TV router and gateway nodes. Digital Power Corporation (NYSEMKT:DPW) said that the contracts could fetch it an average of $1.3 million in revenue in a period of five years based on the current purchase forecasts. However, it said the customers may adjust their purchase forecasts in the future. Digital Power Corp. (NYSEMKT:DPW) ended the last trading day at $1.55. Company weekly volatility is calculated as 12.82% and price to cash ratio as 5.21. Digital Power Corp. (NYSEMKT:DPW) showed a weekly performance of 19.84%.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Sept. 30 announced the publication of two papers highlighting early studies of glembatumumab vedotin in breast cancer and metastatic melanoma in the Journal of Clinical Oncology (JCO). The papers, “A Phase 1/2 Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Advanced Melanoma” and “A Phase 1/2 Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients with Locally Advanced or Metastatic Breast Cancer” have been published as Early Release Articles on JCO’s website and will appear in a future print edition. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares increased 0.23% in last trading session and ended the day at $13.18. CLDX return on assets is -36.10%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly performance is -7.90%.